Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting medicines, known simply as TCEs, are being adopted from the oncology ...

Ouro’s series A was co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners. Monograph Capital participated in the round and also founded the company in partnership with GSK ...

On Friday, San Francisco-based Ouro emerged from stealth revealing $120 million in funding from backers that include GSK, which helped form the young company. “Fundamentally, we think this could ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

B cells, like those pictured above, malfunction in autoimmune diseases and are the target of a number of CAR-T therapies in clinical testing.

Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ... The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...